HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Citation:

Klein, Florian, et al. “HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.”. Nature 492.7427 (2012): , 492, 7427, 118-22. Web.

Date Published:

2012 Dec 06

ISSN:

1476-4687

Abstract:

Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range of viral isolates in vitro and protect non-human primates against infection. Previous work showed that antibodies exert selective pressure on the virus but escape variants emerge within a short period of time. However, these experiments were performed before the recent discovery of more potent anti-HIV-1 antibodies and their improvement by structure-based design. Here we re-examine passive antibody transfer as a therapeutic modality in HIV-1-infected humanized mice. Although HIV-1 can escape from antibody monotherapy, combinations of broadly neutralizing antibodies can effectively control HIV-1 infection and suppress viral load to levels below detection. Moreover, in contrast to antiretroviral therapy, the longer half-life of antibodies led to control of viraemia for an average of 60 days after cessation of therapy. Thus, combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV-1-infected individuals.

DOI:

10.1038/nature11604

Alternate Journal:

Nature